Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Clin Psychopharmacol ; 42(4): 350-356, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35506599

RESUMEN

PURPOSE: Lamotrigine (LTG) is used for treatment of mood disorders, but it is associated with the risk of rash occurrence in the initial administration phase. Although slow titration reduces this risk, its effectiveness in the treatment of mood disorders has not been verified. The effects of titration method on the safety and effectiveness of LTG for the treatment of mood disorders were examined in this study. METHODS: This retrospective cohort study included 312 patients with mood disorders who underwent initiation of LTG therapy. Data regarding baseline demographics, titration schedules, concomitant medications, and time to and cause of discontinuation of LTG were collected. A multivariate analysis was used to evaluate the effects of the titration schedules. The 12-month effectiveness was also evaluated. RESULTS: The 12-month discontinuation rate of LTG was 16.7%. The most frequent cause of discontinuation was development of a rash (47.7%, n = 312). Fast titration (adjusted odds ratio, 8.15) significantly increased the risk of rash development, and slow titration (adjusted odds ratio, 0.29) significantly decreased this risk. The time to all-cause discontinuation was not significantly different between the slow and standard titration groups (n = 303). After 12 months of treatment, the condition of 46.7% patients were rated much or very much improved using CGI-C. CONCLUSIONS: Although slow titration of LTG reduces the occurrence of a rash, it is not more effective than standard titration in the long term. Optimizing the initial LTG titration schedule for patients with mood disorders is challenging.


Asunto(s)
Exantema , Trastornos del Humor , Anticonvulsivantes/efectos adversos , Exantema/inducido químicamente , Exantema/tratamiento farmacológico , Exantema/epidemiología , Humanos , Lamotrigina/efectos adversos , Trastornos del Humor/tratamiento farmacológico , Estudios Retrospectivos , Triazinas/efectos adversos
2.
Nihon Rinsho ; 70(1): 67-72, 2012 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-22413495

RESUMEN

Psychiatric symptoms associated with endocrine disorders and metabolic disorders have been well recognized. Common endocrine/metabolic disorders that frequently cause psychiatric symptoms, thyroid disease, adrenal disorders, parathyroid disease, diabetes, electrolyte disturbance are reviewed, especially focusing on usage of psychotropic medicine. Psychotropic medication targeting each psychiatric symptom would be recommended for patients with moderate to severe psychiatric symptoms. However, it should be considered that psychotropic medicine might affect background endocrine/metabolic disorders themselves. Risk/benefit of the medication should be deliberated for individual cases.


Asunto(s)
Enfermedades del Sistema Endocrino/complicaciones , Trastornos Mentales/tratamiento farmacológico , Trastornos Mentales/etiología , Enfermedades Metabólicas/complicaciones , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...